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Ventilator-associated pneumonia is the most prevalent nosocomial infection in intensive
care  units and is associated with high mortality rates (14–70%).
Aim: This study evaluated factors inﬂuencing mortality of patients with Ventilator-
associated pneumonia (VAP), including bacterial resistance, prescription errors, and
de-escalation of antibiotic therapy.
Methods: This retrospective study included 120 cases of Ventilator-associated pneumonia
admitted to the adult adult intensive care unit of the Federal University of Uberlândia.
The chi-square test was used to compare qualitative variables. Student’s t-test was used
for  quantitative variables and multiple logistic regression analysis to identify independent
predictors of mortality.
Findings: De-escalation of antibiotic therapy and resistant bacteria did not inﬂuence mor-
tality. Mortality was 4 times and 3 times higher, respectively, in patients who received an
inappropriate antibiotic loading dose and in patients whose antibiotic dose was  not adjusted
for  renal function. Multiple logistic regression analysis revealed the incorrect adjustment
for  renal function was the only independent factor associated with increased mortality.
Conclusion: Prescription errors inﬂuenced mortality of patients with Ventilator-associated
pneumonia, underscoring the challenge of proper Ventilator-associated pneumonia treat-
ment, which requires continuous reevaluation to ensure that clinical response to therapymeets expectations.
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Introduction
Although there have been advances in preventing ventilator-
associated pneumonia (VAP), it remains the most prevalent
nosocomial infection in intensive care units (ICU).1 VAP
impairs patient recovery by increasing length of hospitaliza-
tion, duration of mechanical ventilation, and hospitalization
costs.2 Moreover, VAP is associated with high mortality rates
(14–70%), which are higher in infections due to resistant bacte-
ria, inappropriate antimicrobial therapy use, and incorrect
antimicrobial prescription or de-escalation therapy.3,4
VAP is often caused by resistant bacteria, which may limit
therapeutic options and compromise patient outcomes in
clinical practice.5
As VAP is associated with signiﬁcant morbidity and mor-
tality, the choice of initial empiric treatment should take into
account the risk of infections caused by resistant organisms. In
addition, proper prescription of antimicrobial therapy should
also consider the type, dosage, and duration of drug adminis-
tration. Despite the availability of guidelines for VAP diagnosis
and treatment, therapy still varies signiﬁcantly between insti-
tutions and the occurrence of incorrect therapy prescription
is quite high, ranging from 10% to 73%.6,7
The aim of this study was to evaluate factors inﬂuenc-
ing the mortality of patients diagnosed with VAP, including
bacterial resistance, prescription errors, and de-escalation of
antimicrobial therapy.
Methods
This retrospective study reviewed medical records of patients
admitted to the adult ICU of the Federal University of Uber-
lândia (Adult ICU/UFU), between January 1st and July 31st,
2013. The patients included in the study were 18 years or
older who were diagnosed with VAP. Diagnosis was based
on criteria established by the American Thoracic Society and
the Infectious Diseases Society of America,8 including: mechan-
ical ventilation for at least 48 h and appearance of new or
progressive pulmonary inﬁltrate on chest radiographs asso-
ciated with at least two clinical signs and/or laboratory
changes suggesting an ongoing infection, including fever
(>38 ◦C) or hypothermia (<35 ◦C); leukocytosis (>10,000/mm3)
or leukopenia (<4000/mm3); purulent tracheal secretions; and
oxygenation changes.
Out of the total of 467 medical records of patients admit-
ted to the Adult ICU/UFU during the study period analyzed,
there were 132 cases of VAP in 120 patients, since 12 patients
had two  episodes of infection. In patients who had more than
one episode of VAP diagnosed during the study period, we
included only the ﬁrst identiﬁed case of VAP. The study was
approved by the Ethics Committee of the Federal University
of Uberlândia (protocol number 775.657) and registered as a
clinical trials service of the U.S. National Institutes of Health
(protocol number 30121978).Medical records were abstracted to obtain information on
patient age, gender, primary diagnosis at admission, comor-
bidities, prognostic indexes (Acute Physiology and Chronic
Health Disease Classiﬁcation System II [APACHE II] and 1 6;2  0(5):437–443
Simpliﬁed Acute Physiology Score III [SAPS III]); causative
bacteria identiﬁed and sensitivity proﬁles, the characteris-
tics of antimicrobial prescriptions, and outcome (discharge or
death).
Based on data in the medical records, speciﬁcs about pre-
scription and administration of antimicrobial therapy were
obtained, including whether treatment was administered
after having obtained the results of sensitivity proﬁling using
quantitative culture, as well as de-escalation (interruption of
antimicrobial treatment or replacement by an antimicrobial
with limited-spectrum coverage); escalation (addition of a new
antimicrobial or replacement by a broad-spectrum antimicro-
bial); or maintenance (maintenance of antimicrobial initially
prescribed or replacement by an antimicrobial with the same
coverage proﬁle).8
Errors in antimicrobial prescription were classiﬁed as fol-
lows: inappropriate choice (different choice from literature
recommendations); errors in loading or maintenance dose
(prescription of a higher or lower dose compared to the indi-
cated dose); errors in the interval between doses (higher
or lower interval between doses compared to the indicated
interval); delay in starting antimicrobial therapy (more than
one hour between prescription and administration of the
ﬁrst antimicrobial dose); inappropriate adjustment for body
weight (no dose correction based on patient weight); inap-
propriate adjustment for renal function; errors in treatment
duration (prescription for shorter or longer duration than
the indicated period). To analyze treatment adequacy based
on the literature, we used guideline recommendations for
management and health care of adults with nosocomial
pneumonia associated with mechanical ventilation from the
American Thoracic Society and the Infectious Diseases Society of
America.8 The Sanford Guide to Antimicrobial Therapy8 were
used as standards for decisions about starting time; dose
and indicated dosage; and adjustments, when necessary, for
weight and renal function.9 Error in starting of antibiotic ther-
apy was deﬁned by the Surviving Sepsis Campaign10 as more
than one hour between prescription of the ﬁrst antibiotic
dose by the attending physician and administration to the
patient.
Multidrug-resistant bacteria were deﬁned as bacteria resis-
tant to three or more  classes of antimicrobials. Gram-positive
bacteria were assessed for oxacillin resistance.9 According
to local characteristics the resistance proﬁle of the Adult
ICU/UFU has been deﬁned as follows: Staphylococcus aureus and
Staphylococcus epidermidis sensitive or not to oxacillin (MRSA),
Pseudomonas aeruginosa and Acinetobacter baumannii resistant
to carbapenems (imipenem and meropenem), enterobacteri-
aceae (Escherichia coli, Enterobacter spp, Klebsiella pneumoniae spp,
Serratia spp) for the production of beta-lactamase extended
spectrum (ESBL) and Stenotrophomonas maltophilia resistant to
trimethoprim/sulfamethoxazole.
Statistical  analysis
Chi-square test was used to compare qualitative variables.
Student’s t test was used to compare means between groups
of normally distributed quantitative variables.
Multiple logistic regression analysis was used to evaluate
mortality independent predictors in the ICU. SPSS Statistics for
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Table 1 – Clinical characteristics and prognosis based on clinical outcomes of discharge or death among patients
diagnosed with ventilator-associated pneumonia.
Discharge Death p-Value
Age (years) 41 ± 15 61 ± 18 0.000a
Days of hospitalization (average) 29 ± 19 days 47 ± 33 days 0.001a
Prognostic indexes
APACHE II (scores) 18.2 ± 7.2 21.7 ± 7.1 0.028a
Mortality APACHE II (%) 25 ± 18 38 ± 25 0.003a
SAPS III Admission (scores) 57.7 ± 13.3 67.7 ± 15.3 0.001a
Mortality SAPS III Admission (%) 35 ± 20 49 ± 24 0.002a
Diagnosis at admission n  (%) n  (%)
Neurologic 35 (2) 13 (11) 0.131
Trauma 26 (2) 2 (2) 0.001a
Respiratory 6 (5) 8 (7) 0.091
Infectious 5 (4) 7 (6) 0.101
Cardiovascular 2 (1) 10 (8) 0.001a
Othersb 2 (2) 4 (3) 0.260
Comorbidities n (%) n  (%)
Smoking 12 (10) 3 (4) 0.513
SAH 12 (10) 2  (2) 0.001a
Alcoholism 12 (10) 2 (2) 0.130
DM 2 (3) 7 (8) 0.008a
Heart disease 1 (1) 7 (9) 0.000a
Lung disease 1 (1) 4 (3) 0.039a
SAH, systemic arterial hypertension, DM, diabetes mellitus; APACHE II, Acute Physiology and Chronic Health Disease Classiﬁcation System II;
SAPS III, Simpliﬁed Acute Physiology Score II.
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Table 2 – Bacteriological proﬁle of patients diagnosed
with ventilator-associated pneumonia who were
admitted to the adult intensive care unit of the Hospital
de Clinicas of the Federal University of Uberlândia.
Bacteria General Resistant
n % n %
Pseudomonas aeruginosaa 42 30.8 20 47.6
Staphylococcus aureusb 30 23.8 11 36.7
Acinetobacter baumanniia 26 19.0 18 69.2
Serratia sppd 10 7.4 4 40.0
Stenotrophomonas maltophiliac 10 7.4 0 0.0
Klebsiella pneumoniae sppd 8 5.9 5 62.5
Enterobacter sppd 6 4.4 1 15.0
Escherichia colid 2 1.5 1 50.0
Staphylococcus epidermidisa 2 1.5 1 50.0
All bacteria 136 100 62 45.6
a Resistant to carbapenems (imipenem and meropenem).
b Resistant to oxacillin (multidrug resistant Staphylococcus aureus).
c Resistant to trimethoprim/sulfamethoxazole.
d Producers of extended-spectrum beta-lactamase. In 16 patientsa p < 0.05.
b Burned and pancreatitis.
indows was used for analysis, and results were considered
tatistically signiﬁcant when p < 0.05.
esults
f patients included in this study, 32% were diagnosed with
AP in the Adult ICU/UFU during the study period. An over-
ll mortality rate of 35% of patients with VAP was observed.
he patients were predominantly male (74%), with an average
ge of 49 ± 19 years, average time of hospitalization of 35 ± 26
ays, and average admission APACHE II and SAPS III prognostic
ndex scores of 19.5 ± 7.5 and 61.9 ± 15, respectively.
Patient clinical characteristics, prognostic index scores,
nd discharge or death outcomes in the ICU are shown in
able 1. The mortality rate was higher in older patients
nd those with higher prognostic index scores. Cardiovascu-
ar failure was the most frequent reason for hospitalization
p = 0.000). Analysis of comorbidities revealed a signiﬁcant cor-
elation between death and diabetes (p = 0.008), heart disease
p = 0.000), and lung disease (p = 0.039). The average duration of
ospitalization was 38% higher in the group of patients who
ied (p = 0.001) (Table 1).
Multi-drug resistant microorganisms were detected in
5.6% of infections, 69.2% of which were caused by A. bau-
annii, 47.6% by P. aeruginosa,  36.7% by S. aureus, and 42.3%
y extended spectrum -lactamase producing bacteria. No
arbapenemase-producing bacteria were observed (Table 2).
here was no observed difference in mortality rates amongwere identiﬁed more than one microorganisms.
infections caused by resistant or susceptible organisms (27%
vs. 46%, p = 0.104).
Initial antimicrobial therapy was maintained, escalation,
and de-escalation in 57%, 33%, and 10% of cases, respectively.
There were no differences in mortality rates among cases in
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Table 3 – Evaluation of factors affecting outcomes of patients diagnosed with ventilator-associated pneumonia.
Discharge Death p-Value
n (%) n (%)
Age >60 years 11(13.4) 32 (13.4) 0.000a
ICU admission >21 days 48 (58.5) 33 (58.5) 0.106
Prescription errors n (%) n (%) p-Value
Error in loading dose 1 (1) 4 (8) 0.031a
Error in maintenance dose 12 (15) 11 (22) 0.304
Error in the interval between doses 18 (22) 10 (20) 0.964
Delay in starting antimicrobial therapy 57 (70) 28 (56) 0.223
Inappropriate adjustment for renal function 5 (6) 15 (30) 0.000a
Error in treatment duration 9 (89) 4 (8) 0.299
Conduct n (%) n (%) p-Value
De-escalation 10 (12) 2 (4) 0.160
Continuation 30 (37) 12 (24) 0.685
Maintenance 42 (51) 32 (72) 0.419
Bacteria n (%) n (%) p-Value
Pseudomonas aeruginosa MRa 9 (41) 11 (55) 0.087
Acinetobacter baumannii MRa 9 (64) 9 (75) 0.254
Staphylococcus aureus MRb 10 (30) 1 (20) 0.914
a Resistant to carbapenems (imipenem and meropenem).
R = mb Resistant to oxacillin (multidrug resistant Staphylococcus aureus); M
which treatment was de-escalated compared to cases in which
it was maintained or escalated (16.6% vs. 33.3%, p = 0.160).
The most common error in antimicrobial prescriptions was
delay in starting treatment, followed by the interval between
doses. Analysis of the inﬂuence of prescription errors on mor-
tality rate revealed a 4-fold increase in mortality in patients
who  received an inappropriate loading dose (p = 0.031), and a
3-fold increase when the dosage was not adjusted for renal
function (p = 0.000) (Table 3).
Multiple logistic regression analysis revealed the incorrect
adjustment for renal function was the only independent factor
associated with increased mortality (Table 4).
Discussion
Although guidelines for VAP treatment are available, it
remains the most prevalent infection in the ICU and is asso-
ciated with high mortality rates.3 The high mortality rate in
patients with VAP in this study (35%) is similar to rates of
32.1%1 and 44.3%11 reported in other Brazilian investigations,
as well as a review study in which the rate varied from 14% to
70%.12–15
The higher mortality rates in older patients were likely due
to impaired functional status with advancing age. This obser-
vation was supported by a study in which age over 55 years
was an independent predictor of mortality in patients with
VAP (p = 0.005).11 Chronic diseases such as diabetes mellitus
as well as heart and lung disease were associated with poor
prognosis of patients with VAP. This ﬁnding also reported by
Resende et al., in which the presence of comorbidities was
signiﬁcantly associated with mortality (p = 0.029).16ultidrug resistant; ICU = intensive care unit.
The predominance in this study of Gram-negative bacteria,
including P. aeruginosa and A. baumannii,  is similar to reports
from other countries in South America,17 the United States,18
and Turkey.19 VAP is often related to high rates of resistant
bacteria.20 The incidence of multi-drug resistant Acinetobacter
and Pseudomonas is increasing and had been associated with
increased ICU stays, mechanical ventilation, and possibil-
ity of inappropriate treatment in patients receiving standard
therapy.5,18,19,21
The lack of association between bacterial resistance
and mortality has also been described in the literature22
and can be explained by differences between study popu-
lations, preexisting comorbidities, infection severity, and
rate of inappropriate empirical treatment. Several studies
have demonstrated that the association between mortality
and antimicrobial resistance differed from our sample with
respect to age, as we  included older patients, compared to an
average age of 63.4 years23 and 62.3 years,24 and with higher
rate of comorbidities. Heart disease and lung diseases were
reported in 25% and 20% of patients, respectively.24 These ﬁnd-
ings reinforce the association between increasing impairment
of functional status with age, and the presence of chronic dis-
eases.
The Surviving Sepsis Campaign emphasizes the importance
of daily reevaluation of antimicrobial therapy based on the
results of culture proliferation assays with the aim of dis-
continuing treatment, when possible, to reduce antimicrobial
resistance, toxicity, and costs.10 High rate of antibiotic mainte-
nance (57% of maintenance vs 43% de-escalation or escalation)
has been described in the literature.6 Rello et al.4 consid-
ered the low percentage of therapy de-escalation to be due
to the high rate of infection caused by multi-drug resistant
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Table 4 – Multiple logistic regression analysis of death predictors in ventilator-associated pneumonia in the adult
intensive care unit of the Hospital de Clinicas of the Federal University of Uberlândia.
Death CI (95%)
Frequency OR Lower limit Upper limit
Discontinued 02 3.439 0.436 27.100
Error in loading dose 04 6.254 0.456 85.725
Error in maintenance dose 09 1.232 0.248 6.116
Error of the interval between doses 09 0.391 0.082 1.865
Delay in starting antimicrobial therapy 25 0.877 0.284 2.710
Inappropriate adjustment for renal function 15 8.756 1.803 42.531
Error in the duration treatment 02 0.178 0.023 1.409
Age >60 years old 29 0.137 0.047 1.398
ICU admission >21 days 18 1.034 0.374 2.883
Pseudomonas aeruginosa 20 0.297 0.082 1.075
Acinetobacter baumannii 12 0.318 0.079 1.279
Staphylococcus aureus 5 1.367 0.326 5.742
Multi-drug resistant bacteria 20 0.848 0.326 5.742
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cR2 of 0.674; OR = odds ratio; CI = conﬁdence interval.
acteria including non-glucose fermenting strains (P. aerugin-
sa and A. baumannii)  that were also prevalent in our sample
opulation. Although intended to reduce possible antimicro-
ial resistance, toxicity, and costs, treatment de-escalation is
ess likely for infections caused by drug-resistant infections,
s also described by Alvarez-Lerma et al.25 They reported that
eduction of the initial spectrum of antibiotics occurred only
n 23% of patients infected with resistant pathogens compared
o 68% of patients infected with sensitive microorganisms
p < 0.001).
A  multicenter study conducted in the United States,6 as
ell as investigations carried out in Spain4 and Greece,26
ound that mortality rates were signiﬁcantly reduced after
e-escalation of antibiotic treatment. However, subsequent
nvestigations, including our study, did not ﬁnd any correla-
ion between treatment de-escalation and patient mortality.25
he different results after evaluating the inﬂuence of therapy
e-escalation on mortality were possibly due to confounding
actors. Among these is the difﬁculty in distinguishing the
nﬂuence on mortality rates due to treatment de-escalation
tself or administration an appropriate therapy, since a
orrelation between appropriate therapy and higher de-
scalation rates has been observed.27 In one study, Giantsou
t al.26 included only patients receiving appropriate therapy
nd observed signiﬁcantly lower mortality rates after ther-
py de-escalation compared to maintenance. Differences in
ntimicrobial susceptibility may also explain different mor-
ality rates, as observed in a multicenter study that found
igniﬁcantly lower mortality rates when therapy was discon-
inued (p = 0.001). However, the rate of infection by resistant
acteria was much lower than in our study, which might have
nﬂuenced the differences in observed results.6
Error in starting antibiotic administration, the most fre-
uently detected error in our study, probably occurred due
o a lack of communication between multidisciplinary teams
o immediately initiate the antibiotic as soon as VAP was
iagnosed. The complex system of drug prescription also
ncluded other circumstances that contribute to errors, such
s lack of attention, excessive workload, lack of communi-
ation between teams, and lack of knowledge and trainingof prescribing physicians. Errors in prescribing antimicrobial
agents cause short- and long-term consequences that are
not just restricted to individuals: they can lead not only to
inadequate clinical response and increased morbidity and
mortality, but also involve the community by contributing to
increased bacterial resistance.28 The lack of increased mortal-
ity in patients with delayed start of antibiotic treatment in this
study disagreed with other reports emphasizing the relation-
ship between early administration of antibiotics and reduced
mortality, as reported by Levy et al.,29 in which the admin-
istration of antibiotics within the ﬁrst hour after diagnosis of
severe sepsis and septic shock reduced the mortality rate from
37% to 30.8% (p = 0.001).
In this study, prescription of inappropriate antimicrobial
loading doses and not adjusting dosage for renal function were
determinant factors related to increased mortality. The 4-fold
increased mortality (p = 0.031) observed in patients with inap-
propriate loading dose was probably due to an inability to
reach proper antimicrobial concentrations at the target site.
The lack of knowledge and attention in the initial administra-
tion of higher doses or at shorter intervals were determinant
for the development of unfavorable outcomes among these
patients.
Although renal function was evaluated daily in the adult
ICU of the Federal University of Uberlândia, a signiﬁcant num-
ber of errors in adjusting for renal function caused a 3-fold
increase in mortality rate (p = 0.000). In addition, incorrect
adjustment for renal function was the only independent factor
associated with mortality in the multiple logistic regression
analysis. This error was probably due to a lack of attention to
adjust for current creatinine clearance, ease of copying elec-
tronic prescriptions from the previous day, and negligence
in prescribing an extra dose after hemodialysis. The nega-
tive inﬂuence on the outcome of these patients was due to
the deleterious effects induced by toxic levels of antimicrobial
agents when the indicated dose was not reduced, or not to
reach the appropriate therapeutic level when the extra dose
after hemodialysis was not recommended. These factors were
described by Carneiro et al.,30 who reported a very high rate
(43.7%) of inappropriate adjustment for renal function.
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Prescription errors inﬂuenced the mortality rates of
patients with VAP, underscoring the challenge of proper VAP
treatment, which requires continuous reevaluation to ensure
that clinical response to therapy meets expectations.
The limitation of this study is due to retrospective design,
since the data were obtained from information abstracted
from medical records.
Conclusions
In conclusion, this study observed that de-escalation of antibi-
otic therapy and VAP due to resistant bacteria did not inﬂuence
mortality rates. Inappropriate loading dose and lack of adjust-
ment for renal function were more  frequent in patients who
died. Multiple logistic regression analysis revealed the incor-
rect adjustment for renal function was the only independent
factor associated with increased mortality.
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